0001062993-22-007530.txt : 20220311
0001062993-22-007530.hdr.sgml : 20220311
20220311184223
ACCESSION NUMBER: 0001062993-22-007530
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220309
FILED AS OF DATE: 20220311
DATE AS OF CHANGE: 20220311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Montecalvo Antonio S.
CENTRAL INDEX KEY: 0001759261
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37906
FILM NUMBER: 22734660
MAIL ADDRESS:
STREET 1: C/O ORGANOGENESIS INC.
STREET 2: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organogenesis Holdings Inc.
CENTRAL INDEX KEY: 0001661181
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-575-0775
MAIL ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp.
DATE OF NAME CHANGE: 20151215
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-03-09
0001661181
Organogenesis Holdings Inc.
ORGO
0001759261
Montecalvo Antonio S.
C/O ORGANOGENESIS HOLDINGS INC.
85 DAN ROAD
CANTON
MA
02021
0
1
0
0
Vice President, Health Policy
Class A Common Stock
2022-03-09
4
S
0
10000
8.52
D
73221
D
Class A Common Stock
2022-03-10
4
M
0
46103
3.46
A
119324
D
Class A Common Stock
2022-03-10
4
M
0
22401
3.46
A
141725
D
Class A Common Stock
2022-03-10
4
S
0
97436
8.39
D
44289
D
Stock Option (Right to Buy)
3.46
2022-03-10
4
M
0
46103
0
D
2027-05-04
Class A Common Stock
46103
55397
D
Stock Option (Right to Buy)
3.46
2022-03-10
4
M
0
22401
0
D
2027-05-04
Class A Common Stock
22401
78175
D
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.42, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.
/s/ William R. Kolb, Attorney-in-Fact
2022-03-11